NONLINEAR PHARMACOKINETIC CHARACTERISTICS OF 5-FLUOROURACIL (5-FU) IN COLORECTAL-CANCER PATIENTS

被引：50
|
作者：
SCHAAF, LJ
DOBBS, BR
EDWARDS, IR
PERRIER, DG
机构：
[1] UNIV OTAGO,SCH MED,DEPT PHARM,DUNEDIN,NEW ZEALAND
[2] UNIV OTAGO,SCH MED,MRC NEW ZEALAND,TOXICOL RES UNIT,DUNEDIN,NEW ZEALAND
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1987年 / 32卷 / 04期
关键词：
D O I：
10.1007/BF00543978
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：411 / 418
页数：8
相关论文
共 50 条
  • [1] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [2] THE RELATIONSHIP BETWEEN PLASMA PHARMACOKINETICS AND TISSUE METABOLITES OF 5-FLUOROURACIL (5-FU) IN PATIENTS WITH COLORECTAL-CANCER
    FINAN, PJ
    CHISHOLM, EM
    WOODHOUSE, L
    GILES, GR
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1987, 13 (04): : 349 - 353
  • [3] Pharmacokinetic (PK) guided optimization of 5-fluorouracil (5-FU) dosing in the treatment of patients with colorectal cancer (CRC)
    Goal, Gaurav
    Chu, Edward
    Sun, Min
    Meisner, Dennis James
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [5] Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens
    Bajetta, E
    DiBartolomeo, M
    Somma, L
    DelVecchio, M
    Artale, S
    Zunino, F
    Bignami, P
    Magnani, E
    Buzzoni, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 687 - 690
  • [6] COMBINATION CHEMOTHERAPY CONTAINING SEMUSTINE (MECCNU) IN PATIENTS WITH ADVANCED COLORECTAL-CANCER PREVIOUSLY TREATED WITH 5-FLUOROURACIL (5-FU)
    ENGSTROM, PF
    MACINTYRE, JM
    DOUGLASS, HO
    MUGGIA, F
    MITTELMAN, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1983, 6 (02): : 175 - 180
  • [7] A COMPARISON OF 5-FLUOROURACIL(5-FU) LEUCOVORIN WITH OTHER CURRENT CHEMOTHERAPEUTIC REGIMENS IN THE TREATMENT OF METASTASIZING COLORECTAL-CANCER
    BAUR, M
    SCHLAPPACK, O
    HAVELEC, L
    MADER, R
    MAROSI, C
    SCHEITHAUER, W
    DITTRICH, C
    WIENER KLINISCHE WOCHENSCHRIFT, 1991, 103 (11) : 332 - 339
  • [8] BAKER ANTIFOL (BAF) IN COMBINATION WITH METHYL CCNU AND 5-FLUOROURACIL (5-FU) FOR THE TREATMENT OF METASTATIC COLORECTAL-CANCER
    SHAW, MT
    HEILBRUN, LK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 300 - 300
  • [9] Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC)
    Goel, Gaurav
    Sehgal, Rajesh
    Meisner, Dennis James
    Sun, Min
    Pasricha, Gurleen
    Chu, Edward
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] HIGH-DOSE LEUCOVORIN (CF), 5-FLUOROURACIL (5-FU) AND CISPLATIN (CIS) CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL-CANCER
    SCHEITHAUER, W
    DEPISCH, D
    SCHIESSEL, R
    ZIELINSKI, C
    PREIS, P
    GISSLINGER, H
    LUDWIG, H
    BLUT, 1988, 57 (04): : 206 - 206
12345